SynthesisThe Laryngoscope2026
Incidence and Risks of Chronic Rhinosinusitis in Head and Neck Cancer: A Meta-Analysis.
Synthesis in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSeveral studies have described the occurrence of chronic rhinosinusitis (CRS) in adult patients with head and neck cancers (HNC). The goal of this review is to identify the incidence and risk factors for CRS in adult patients with HNC. DATA SOURCES: PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials. REVIEW
methodsA systematic search was performed from inception to July 2025 and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol. Studies that looked at the development of CRS following treatment of HNC were included.
resultsSeventeen studies representing a total of 3685 patients were pooled. There was significant heterogeneity in how CRS was diagnosed. The overall pooled incidence of CRS in all HNC patients was 0.37 (95% CI, 0.27-0.47). The incidence was significantly higher in patients with nasopharyngeal cancer (NPC) (0.45 vs. 0.18, p < 0.001). The maxillary sinuses were the most common sinuses involved with an incidence of 0.60 followed by the ethmoid sinuses at 0.45. Radiation therapy was associated with a higher risk of CRS (log OR = 1.46, 95% CI of 0.76, 2.16), especially in patients with NPC (log OR of 1.82 vs. log OR of 0.52, p = 0.01). Qualitative review showed that concurrent chemotherapy and advanced disease stage also increased the risk of CRS.
conclusionsThe presence of NPC, radiation therapy, advanced stage, and concurrent chemotherapy significantly increases the risk of CRS in patients with head and neck cancers. Clinicians should be aware of the risk when treating these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.